Detailed Information

Cited 4 time in webofscience Cited 4 time in scopus
Metadata Downloads

Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark-time analysis

Authors
서화정오현숙
Issue Date
17-Dec-2021
Publisher
한국역학회
Keywords
Type 2 diabetes mellitus; Anticancer agents; Medication compliance; Metformin; Drug prescription
Citation
Epidemiology and Health, v.43, pp.1 - 9
Journal Title
Epidemiology and Health
Volume
43
Start Page
1
End Page
9
URI
https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84087
DOI
10.4178/epih.e2021103
ISSN
1225-3596
Abstract
OBJECTIVES: This study investigated the effectiveness of early medication treatment and metformin use for cancer prevention in type 2 diabetes patients. METHODS: Population-based cohort data were used from the Korean National Health Insurance Service-National Sample Cohort database (KNHIS-NSC) for 2002–2013. Patient-specific medication prescription status was defined by the landmark time (LMT; a fixed time after cohort entry), considering both pre- and post-LMT prescriptions to control methodological biases in observational research. The LMT was set to 2 years. Logistic regression analysis with multivariable adjustment was conducted to analyze cancer incidence by patient-specific medication prescription status. RESULTS: Only 33.4% of the subjects were prescribed medication early (before the LMT) with compliance. Cancer incidence in individuals with early prescription and compliance was 25% lower (odds ratio [OR],0.75; 95% confidence interval [CI], 0.67 to 0.84) than in those without. As early-prescribed medications, metformin monotherapy and metformin combination therapy were associated with 34% (OR, 0.66; 95% CI, 0.51 to 0.83) and 25% (OR, 0.75; 95% CI, 0.64 to 0.88) lower cancer risk than nonuse, respectively. Patients who were prescribed late (post-LMT) but did not comply with the prescription had a 24% (OR, 1.24; 95% CI, 0.97 to 1.58) higher cancer incidence than non-users. Among patients who started monotherapy early without changes throughout the entire follow-up period, those who started on metformin had a 37% (OR, 0.63; 95% CI, 0.41 to 0.99) lower risk of cancer than non-metformin users. CONCLUSIONS: Doctors must prescribe antidiabetic medication early, and patient compliance is required, regardless of the prescription time, to prevent cancer. Metformin monotherapy or combination therapy is recommended as an early prescription.
Files in This Item
There are no files associated with this item.
Appears in
Collections
사회과학대학 > 응용통계학과 > 1. Journal Articles
사회과학대학 > 의료경영학과 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Oh, Hyun Sook photo

Oh, Hyun Sook
Social Sciences (Department of Applied Statistics)
Read more

Altmetrics

Total Views & Downloads

BROWSE